Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR

Documenti analoghi

• Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer
  di: Iwama, Eiji, et al.
  Pubblicazione: (2014)
• Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer harboring EGFR mutations
  di: Tanaka, Kentaro, et al.
  Pubblicazione: (2017)
• Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR‐tyrosine kinase inhibitors
  di: Furuyama, Kazuto, et al.
  Pubblicazione: (2013)
• Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression
  di: Li, Heyan, et al.
  Pubblicazione: (2014)
• The detectability of the pretreatment EGFR T790M mutations in lung adenocarcinoma using CAST-PCR and digital PCR
  di: Tatematsu, Tsutomu, et al.
  Pubblicazione: (2017)